A5066402029- Renal Diseases and Glomerulopathies
- Platelet Disorders and Treatments
- Chronic Kidney Disease and Diabetes
- Autoimmune Bullous Skin Diseases
- Pregnancy and preeclampsia studies
- Blood Pressure and Hypertension Studies
- Pregnancy and Medication Impact
- Blood groups and transfusion
- Heart Failure Treatment and Management
- Celiac Disease Research and Management
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Glycosylation and Glycoproteins Research
- Dialysis and Renal Disease Management
- Renal cell carcinoma treatment
- Immunodeficiency and Autoimmune Disorders
- Diabetes Treatment and Management
- Renal and Vascular Pathologies
- Magnesium in Health and Disease
- Potassium and Related Disorders
- Complement system in diseases
- Ion Transport and Channel Regulation
- Mast cells and histamine
- Porphyrin Metabolism and Disorders
- Kidney Stones and Urolithiasis Treatments
Tianjin Medical University General Hospital
2017-2024
Tianjin Medical University
2017-2021
King University
2014-2017
Peking University
2014-2017
Peking University First Hospital
2014-2017
Current therapy for IgA nephropathy mainly includes renin-angiotensin system inhibitors and adding steroids patients with persistent proteinuria. This study aimed to evaluate kidney disease progression its risk factors in a Chinese cohort under current therapy.Patients followed up at least 12 months from prospective database were involved. Renal survival the relationship between clinical parameters composite failure events (defined as end stage or eGFR halving) assessed.Overall, 703 2003...
Aberrant galactose-deficient IgA1 molecules (Gd-IgA1) are important causal factors in IgA nephropathy (IgAN); however, the detection of Gd-IgA1 IgAN is complicated and instable. A monoclonal antibody, KM55, which specifically recognizes has been developed. In present study, we further explored clinical significance using KM55.In this enrolled 75 patients with 80 healthy controls detected plasma levels KM55 ELISA method. We also stained -mesangial deposition KM55.We observed that were...
The features of IgA nephropathy (IgAN) after SARS-CoV-2 infection have not been well characterized. In this study, we compared the clinical and pathological characteristics patients with IgAN who had experienced to those not. We conducted a retrospective study that enrolled 38 biopsy-proven following 4 months (post-SARS-CoV-2 group) 1154 prior pandemic (pre-SARS-CoV-2 group). Among group cases, 61% were females. average duration from renal biopsy was 78.6 days. Prior infection, different...
Endothelial injury is a common manifestation in IgA nephropathy (IgAN). After the previous identification of upregulated soluble fms-like tyrosine kinase-1 (sFlt-1) correlated with endothelial IgAN, present study, we further explored role sFlt-1 IgAN. We enrolled 72 patients IgAN and detected levels. The polymeric IgA1 (pIgA1) complexes were isolated from pooled plasma samples another 10 Apoptosis proteins cultured human umbilical vein cells (HUVECs) stimulation recombinant or caspase-9...
Abstract Objective To date, nephrotic syndrome (NS) has not been well characterized in patients with IgA nephropathy (IgAN). Whether decline serum albumin is an ominous sign IgAN massive proteinuria remains unknown. In this study, we evaluated clinical and pathological features of NS compared the differences for these long-term outcomes between nephrotic-range proteinuria. Methods A retrospective study was conducted, enrolling 1013 biopsy-proven IgAN. The primary endpoint composite a...
Abstract Background Immunoglobulin A nephropathy (IgAN) is the leading cause of end-stage kidney disease. Previous mRNA microarray profiling studies IgAN revealed inconsistent data. We sought to identify aberrantly expressed genes and biological pathways by integrating gene expression datasets in blood cells performing systematically experimental validation. also explored relationship between target galactose-deficient IgA1 (Gd-IgA1) IgAN. Methods retrieved Gene Expression Omnibus (GEO)...
Introduction: There are conflicting opinions regarding the use of immunosuppressant treatment in IgA nephropathy (IgAN) patients with an estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73 m2 and persistent proteinuria a daily excretion ≥1.0 g. Methods: This retrospective study involved 110 IgAN for whom clinical data were available; these, 90 had complete follow-up data. Patients grouped based on whether they received immunotherapy during follow-up, their renal function,...
Background: Our previous study revealed that plasma levels of a-2,6-sialyltransferase 1 (ST6GAL1) were increased in patients with IgA nephropathy (IgAN). ST6GAL1 catalyzes terminal sialylation IgG to shift the antibody effector function anti-inflammatory pattern. However, role progression IgAN and underlying mechanisms are still unknown. Methods: A total 180 included. The kidney outcomes defined as eGFR decline or proteinuria remission. Peripheral blood mononuclear cells (PBMCs) either...
Abstract Galactose‐deficient IgA1 (Gd‐IgA1) plays a crucial role in the development of Immunoglobulin A nephropathy (IgAN), however, underlying pathogenic mechanisms driving Gd‐IgA1 production B cells are not well understood. In this study, RNA‐seq analysis identified 337 down‐regulated and 405 up‐regulated genes from 17 patients with IgAN 6 healthy controls. Among them, ST6Gal1, which was associated previous genome‐wide association study (GWAS), significantly positive correlated elevated...
Recent genomewide association study suggested that the top single-nucleotide polymorphism, rs978056, in HECW1 gene (which encodes HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1) associated with levels of galactose-deficient IgA1 (Gd-IgA1) IgA nephropathy (IgAN). However, expression IgAN has not yet been examined.In following study, we have enrolled 40 patients healthy controls. The level HECW1, as well plasma Gd-IgA1 IgA1, were determined detected.IgAN presented...